Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

Theratechnologies Inc T.TH

Sector: Healthcare | Sub-Sector: Biotechnology
Alternate Symbol(s):  THERF

Theratechnologies, Inc. is a biopharmaceutical company that specializes in therapeutic peptide products, with an emphasis on growth-hormone releasing factor, or GRF, peptides.
Price: $0.36 | Change: $0.00 | %Change: 0.00%
Volume: 20,272 | Day High/Low: 0.37/0.36 | 52 Week High/Low: 0.65/0.325
View modes: 
0 stars

RE:RE:RE:RE:RE:Fidelity

Fidelity is at it again today!!!  rate and reply
3 stars

2015

2015 should see EBITDA of at least 5 million and this will all be tax free considering the loss carry forward.  If sales can accelerate with better branding and messaging, the upside is enormous.   It...read more
0 stars

RE:RE:RE:RE:Fidelity

I share your optimism. Sales during the fiscal fourth quarter of 2014, however, are not the issue as sales were just restarting from a complete stop. The number to focus on is the number of patients...read more
0 stars

RE:RE:RE:Fidelity

6000 shares traded at .405 65000 share traded in THERF @ about .43 Maybe sales won't be stellar in this past quarter. Apparently all patients have been sent a letter notifying them of Egrifta...read more
0 stars

RE:RE:Fidelity

141k shares traded in THERF also...  rate and reply
0 stars

RE:Fidelity

Fidelity doing most of the buying again today,,,..  rate and reply
0 stars

Sorry for multiple post

My bad!!!  rate and reply
0 stars

Fidelity

Did some serious buying at end of day We need many more trading days like today Maybe finally some positive news  rate and reply
0 stars

Fidelity

Did some serious buying at end of day We need many more trading days like today Maybe finally some positive news  rate and reply
0 stars

Fidelity

Did some serious buying at end of day We need many more trading days like today Maybe finally some positive news  rate and reply
0 stars

RE:Pooya Hemami used to be the analyst at Desjardins covering

original source How to Bargain Hunt for Hot Biotechs: Edison's Pooya Hemami Source: Peter Byrne of The Life Sciences Report  (10/15/14) Every business day, Edison Investment Research Analyst Pooya...read more
0 stars

After six weeks of selling Egrifta again

The PPS has gone from 59 cents to 37.5 cents in six weeks.  I hope it is not an indication of how well the selling is going.  rate and reply
5 stars

RE:Euro Pacific Raise Price Target to $1 and rating to Spec Buy

Same guy who had a 12$ target price for TH while he was at Versant Partners couple years ago Lolllllll This company has the worst management team around...and by far! Never again...  rate and reply
5 stars

Euro Pacific Raise Price Target to $1 and rating to Spec Buy

Euro Pacific analyst Doug Loe has come out with a new report that raises the price target to $1 and the rating to speculative buy.  rate and reply
0 stars

Pooya Hemami used to be the analyst at Desjardins covering

TH -used to be very bullish on the stock.Interesting to note hat he owns the stock personnally http://internet.itbusinessnet.com/article/How-to-Bargain-Hunt-for-Hot-Biotechs:-Edisons-Pooya-Hemami...read more
0 stars

RE:RE:RE:RE:1 analyst

As you wrote before, proof is in the pudding. We'll get a good idea by February or if by any luck management releases numbers earlier.  rate and reply
0 stars

RE:RE:RE:1 analyst

ecstatic I am not...the only thing that will make me ecstatic is a rising share price based on fabulous results and new marketing approvals .......30% price increase on no sales does no increase the...read more
0 stars

RE:RE:1 analyst

Canada is a much larger market than Israel, and it is barely relevant. You will almost certainly find the price increase to be a wonderful thing in all subsequent quarterly reports. In fact, it will...read more
0 stars

RE:RE:1 analyst

I am not sure if price was the main issue why peak sales only made it up to 1300 patients.  If it wasn't then the extra 30% in revenue would be nice.  Tanguay said that sales are going as expected...read more
0 stars

RE:1 analyst

why did we find out just as a passing comment that Israel had refused the application...Not MATERIAL tANGUAY SAID....But when Canada approved they made a big fuss....Is Canada s market more important...read more